Review



procedure proc loess with smoothing factor 0.25  (SAS institute)


Bioz Verified Symbol SAS institute is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    SAS institute procedure proc loess with smoothing factor 0.25
    Mean <t>GIR</t> profiles (PPP for PD). Two profiles each receiving Biocon's Insulin‐70/30 and HUMULIN 70/30 were excluded from the PPP (n = 72) for PD based on C‐peptide exclusion rules and during the blinded database release meeting (because of extended gaps in continuous glucose monitoring), respectively. GIR, glucose infusion rates; PD, pharmacodynamics; PPP, per‐protocol population
    Procedure Proc Loess With Smoothing Factor 0.25, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/procedure+proc+loess+with+smoothing+factor+0%2E25/procedure+proc+loess+with+smoothing+factor+0+25/pmc09543887-148-11-13
    Average 90 stars, based on 1 article reviews
    procedure proc loess with smoothing factor 0.25 - by Bioz Stars, 2026-10
    90/100 stars

    Images

    1) Product Images from "Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US ‐licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE ‐3 ( R ecombinant H uman IN sulin E quivalence‐3) study"

    Article Title: Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US ‐licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE ‐3 ( R ecombinant H uman IN sulin E quivalence‐3) study

    Journal: Diabetes, Obesity & Metabolism

    doi: 10.1111/dom.14768

    Mean GIR profiles (PPP for PD). Two profiles each receiving Biocon's Insulin‐70/30 and HUMULIN 70/30 were excluded from the PPP (n = 72) for PD based on C‐peptide exclusion rules and during the blinded database release meeting (because of extended gaps in continuous glucose monitoring), respectively. GIR, glucose infusion rates; PD, pharmacodynamics; PPP, per‐protocol population
    Figure Legend Snippet: Mean GIR profiles (PPP for PD). Two profiles each receiving Biocon's Insulin‐70/30 and HUMULIN 70/30 were excluded from the PPP (n = 72) for PD based on C‐peptide exclusion rules and during the blinded database release meeting (because of extended gaps in continuous glucose monitoring), respectively. GIR, glucose infusion rates; PD, pharmacodynamics; PPP, per‐protocol population

    Techniques Used: Drug discovery

    Related Articles

    Drug discovery:

    Article Title: Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US ‐licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE ‐3 ( R ecombinant H uman IN sulin E quivalence‐3) study
    Article Snippet: GIR max and other time‐related PD parameters were calculated from smoothed GIR profiles (SAS procedure PROC LOESS with smoothing factor 0.25).



    Similar Products

    procedure proc loess with smoothing factor 0.25  (SAS institute)
    90
    SAS institute procedure proc loess with smoothing factor 0.25
    Mean <t>GIR</t> profiles (PPP for PD). Two profiles each receiving Biocon's Insulin‐70/30 and HUMULIN 70/30 were excluded from the PPP (n = 72) for PD based on C‐peptide exclusion rules and during the blinded database release meeting (because of extended gaps in continuous glucose monitoring), respectively. GIR, glucose infusion rates; PD, pharmacodynamics; PPP, per‐protocol population
    Procedure Proc Loess With Smoothing Factor 0.25, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/procedure+proc+loess+with+smoothing+factor+0%2E25/procedure+proc+loess+with+smoothing+factor+0+25/pmc09543887-148-11-13
    Average 90 stars, based on 1 article reviews
    procedure proc loess with smoothing factor 0.25 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Mean GIR profiles (PPP for PD). Two profiles each receiving Biocon's Insulin‐70/30 and HUMULIN 70/30 were excluded from the PPP (n = 72) for PD based on C‐peptide exclusion rules and during the blinded database release meeting (because of extended gaps in continuous glucose monitoring), respectively. GIR, glucose infusion rates; PD, pharmacodynamics; PPP, per‐protocol population

    Journal: Diabetes, Obesity & Metabolism

    Article Title: Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US ‐licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE ‐3 ( R ecombinant H uman IN sulin E quivalence‐3) study

    doi: 10.1111/dom.14768

    Figure Lengend Snippet: Mean GIR profiles (PPP for PD). Two profiles each receiving Biocon's Insulin‐70/30 and HUMULIN 70/30 were excluded from the PPP (n = 72) for PD based on C‐peptide exclusion rules and during the blinded database release meeting (because of extended gaps in continuous glucose monitoring), respectively. GIR, glucose infusion rates; PD, pharmacodynamics; PPP, per‐protocol population

    Article Snippet: GIR max and other time‐related PD parameters were calculated from smoothed GIR profiles (SAS procedure PROC LOESS with smoothing factor 0.25).

    Techniques: Drug discovery